The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Very positive RNS and some good validation for those who have been a little impatient recently. I worked in food development for ten years and had a hell of a job getting some products to market because of the guidelines for product safety, in both production and the consumer area. One **** up in that process could have poisoned any number of people or called for a product recall which each supermarket will charge you a 250k penalty for. So, you don’t want to get that wrong. In pharma that process has got to be ultimately more complex and risky, and the scrutiny you will be under, for obvious reasons, will be massive. Best to take your time and dot the I’s and t’s than rush and inadvertently f### up, as it’s a long road to be back at the beginning of.
Great post HBD. It helps to be reminded of how tough the process is that a product has to go through to get to market. I used to work in product development and the hoops that you had to jump through there to get a food product to market was tough at times but no where near as complex as what Sar is attempting to do here. I am happy to accept that this stuff takes time. One **** up in that process can put you back to square one. So best not to rush these things.
Great find Ahfam. It's not easy for me to get my head around the science it contains and i cant imagine a company going through the trouble of writing and submitting such a complex piece of work if it was not beneficial to them. I am looking forward to the rns that explains it all in a way that my little brain can understand.
Great link HBD. It answers the question for me about what is to happen to any orphan shares. i think i am just going to top up to a round number. A lot of scaremongering been going on about the price of the big C, your link may help a bit of that to calm down.